PCSK9 and prostate carcinoma: LXR agonist, T0901317, suppressed the development of prostate cancer by upregulating ABCA1 and ABCG1 expression.529 Ezetimibe significantly inhibited the growth of prostate and liver cancers.530,531 Yuan et al. found that the tumor microenvironment could inhibit LDLR expression in CD8+ T cells via activating PCSK9, which suppressed the antitumor activity of CD8+ T cells.532 Therefore, PCSK9 may be a novel target for tumor immunotherapy.